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PTRF: Polymerase I and transcript release factor  
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IAA: iodoacetamide 
DTT: dithiothreitol 
MβCD: Methyl-β-cyclodextrin 
SCX: strong cation exchange chromatography  
IL-6: Interleukin-6 
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Keywords: prostate cancer, prostasome, lipid raft, caveolin, PTRF, kallikrein, IL-6 
3 
 
Summary 
Expression of caveolin-1 is up-regulated in prostate cancer metastasis and is associated with 
aggressive recurrence of the disease. Intriguingly, caveolin-1 is also secreted from prostate 
cancer cell lines and has been identified in secreted prostasomes. Caveolin-1 is the major 
structural component of the plasma membrane invaginations called caveolae. Co-expression of 
the coat protein Polymerase I and transcript release factor (PTRF) is required for caveolae 
formation. We recently found that expression of caveolin-1 in the aggressive prostate cancer cell 
line PC-3 is not accompanied by PTRF, leading to non-caveolar caveolin-1 lipid rafts. Moreover, 
ectopic expression of PTRF in PC-3 cells sequesters caveolin-1 into caveolae. Here we 
quantitatively analyzed the effect of PTRF expression on the PC-3 proteome using Stable Isotope 
Labeling by Amino acids in Culture (SILAC) and subcellular proteomics. We show that PTRF 
reduced the secretion of a subset of proteins including secreted proteases, cytokines and growth 
regulatory proteins, partly via a reduction in prostasome secretion. To determine the cellular 
mechanism accounting for the observed reduction in secreted proteins we analyzed total 
membrane and the detergent-resistant membrane (DRM) fractions. Our data show that PTRF 
expression selectively impaired the recruitment of actin cytoskeletal proteins to the DRM, which 
correlated with altered cholesterol distribution in PC-3 cells expressing PTRF. Consistent with 
this, modulating cellular cholesterol altered the actin cytoskeleton and protein secretion in PC-3 
cells. Intriguingly, several proteins that function in ER to Golgi trafficking were reduced by 
PTRF expression. Taken together, these results suggest that the non-caveolar caveolin-1 found in 
prostate cancer cells generates a lipid raft microenvironment that accentuates secretion pathways, 
possibly at the step of ER sorting/exit. Importantly, these effects could be modulated by PTRF 
expression. 
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Introduction 
Prostate cancer is the most commonly diagnosed cancer in men and the second leading cause of 
cancer related deaths in developed countries. While localized prostate cancer is treatable, 
metastatic recurrence, together with development of androgen-independence, leads to advanced 
prostate cancer which currently has a low survival rate. Caveolin-1, a cholesterol-binding 
integral membrane protein, has been shown to be up-regulated in prostate cancer metastasis and 
is associated with androgen-independence and aggressive recurrence of the disease (1). A 
prostate cancer mouse model showed that genetic ablation of caveolin-1 delays the onset of 
advanced prostate cancer (2), underscoring its importance in prostate cancer progression. Hence 
understanding caveolin-1 action in prostate cancer progression is crucial for the design of novel 
intervention strategies to manage this devastating disease.  
  
Caveolin-1 is a major structural component of caveolae, specialized lipid raft microdomains of 
the plasma membrane characterized by their flask shaped invaginations (3). Lipid rafts and 
caveolae are thought to participate in a variety of cellular processes including lipid regulation, 
endocytosis, cell adhesion, and signal transduction (4). However, a clear delineation between 
lipid rafts and caveolae function remains to be made. Recently, it was revealed that the protein 
Polymerase I and transcript release factor (PTRF), also known as cavin-1, is an essential co-
factor required for stabilization of caveolae at the plasma membrane (5, 6). The loss of PTRF 
results in the loss of caveolae, as well as a decrease in caveolin-1 stability (5). These results 
demonstrate a crucial role for PTRF in caveolae structure and function. Given these new insights, 
the role of PTRF in relation to its function in caveolae is only beginning to be examined in 
prostate cancer (7). 
5 
 
 
Intriguingly, although caveolin-1 is predominately a membrane protein, aggressive prostate 
cancer cell lines have been shown to secrete biologically active caveolin-1 (8). Furthermore, 
secreted caveolin-1 stimulates cell growth and angiogenesis in tumor models (8, 9). Serum 
caveolin-1 has been detected in recurrent prostate cancer after radical prostatectomy and has 
been proposed to be a marker for disease recurrence (8, 10). In addition to classical secretion, 
prostate cells also secrete proteins via membranous storage vesicles referred to as prostasomes.  
It is thought that prostasomes are formed in a similar manner to exosomes, that is, via 
multivesicular bodies which have encapsulated cytoplasmic proteins (11). Prostate epithelial 
cells secrete prostasomes into the prostate fluid where they have important functions related to 
fertility. More recently it has become apparent that prostate cancer cell lines also secrete 
prostasomes and it is thought they may act to modulate the local tumor environment (12-14). 
Prostasome secretion is modulated by cholesterol levels and caveolin-1 has been identified as a 
component of prostasomes in the human prostate carcinoma PC-3 cell line (13). These data have 
prompted us to examine the role of Caveolin-1 and PTRF in secretion of prostate cancer cells.  
 
We have previously shown that PC-3 cells express abundant Caveolin-1 but lack PTRF, and that 
ectopic expression of PTRF in PC-3 cells results in caveolae formation (5). Furthermore, PTRF 
expression in PC-3 cells resulted in reduced directional migration, partly due to attenuation of 
secreted MMP9 (15). Given that caveolin-1 and caveolae participate in a range of cellular 
processes, we undertook quantitative subcellular proteomics analysis using our established PC-3 
cell lines which express GFP-PTRF or GFP (5) in order to acquire a global analysis of changes 
induced by PTRF expression. Systems analysis of the subcellular proteomes points to a role for 
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PTRF in modulating cholesterol dynamics and regulation of the actin cytoskeleton, impacting the 
trafficking of multiple secretion pathways. Importantly, PTRF reduced the secretion of a specific 
subset of proteins including secreted proteases, cytokines and growth factors. Our study reveals 
the potential for PTRF as a therapeutic option that could target a spectrum of secreted factors 
rather than a single molecule. 
 
Experimental Procedures 
Materials: The following materials were obtained from the indicated commercial sources: 
Roswell Park Memorial Institute (RPMI)-1640 medium, L-glutamine, Geneticin (G418) and cell 
culture trypsin were from Life Technologies; Fetal bovine serum (FBS)  was from Bovogen; L-
lysine, L-arginine and L-leucine deficient RPMI-1640, L-leucine, Triton X-100, sodium 
deoxycholate (SDC), MES, dithiotheitol (DTT), iodoacetamide (IAA), filipin III, water-soluble 
cholesterol, protease inhibitors and antibodies against IL-6 and β-actin were from Sigma; 
13
C6
15
N2-lysine and 
13
C6
15
N4-arginine were from Silantes; Sequencing grade modified porcine 
trypsin was from Promega; Antibody against kallikrein 6 was purchased from Santa Cruz; 
Antibodies against caveolin-1 and flotillin were from BD Biosciences; Antibody against filamin 
A was from Millipore; PTRF antibodies were produced by immunizing rabbits with a synthetic 
peptide corresponding to the C-terminal 12 amino acids of mouse PTRF, and affinity purified 
from serum (16). GFP-PTRF has been described previously (5). 
 
Cell culture and SILAC: PC-3, PC-3 GFP and PC-3 GFP-PTRF stable cells were grown and 
maintained in RPMI 1640 medium containing 10% fetal bovine serum. Stable cell lines were 
maintained in 0.1 mg/ml G418. For SILAC experiments, GFP and GFP-PTRF PC-3 cells were 
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maintained in media lacking Lysine and Arginine with dialyzed FBS and supplemented with the 
following amino acids: ‘0/0’ for the normal isotopic Lys and Arg and ‘8/10’ for 13C6
15
N2-Lys 
and 
13
C6
15
N4-Arg. Cell populations were amplified 200-fold in the labeling media to achieve 
>99% incorporation as confirmed by LC-MS/MS. Where required, cells were transfected using 
Lipofectamine 2000 (Life Technologies) according to the manufacturer’s instructions. For each 
analysis, two to three 15 cm plates of PC-3 cells were used per condition for total membrane, 
detergent-resistant membrane extractions, secreted proteome and prostasome extraction.  
 
Isolation of secretome and prostasomes: Briefly, PC-3 cells grown to 60 to 70% confluency 
were washed five times with PBS and then incubated for 24 h in serum free media. Any cell 
debris was removed by centrifugation at 600 g for 10 min at 4 ºC. Cleared cell culture 
supernatant was concentrated through an Amicon 10 kDa cutoff spin column and protein 
concentration was measured using BCA assay. Equal protein levels of secretome prepared from 
the two cell lines were mixed for isolation of prostasomes or in-solution digest. Isolation of 
prostasomes from cleared conditioned media involved sequential centrifugation; 10,000 g 30 min 
4 ºC spin to remove any cell fragments not pelleted at 600 g, then centrifugation of the 
supernatant at 100,000 g, 2 h, 4 ºC. Prostasome pellets were washed with PBS and again pelleted 
at 100,000 g, 2 h, 4 ºC. Pellets were resuspended in 1% sodium deoxycholate.  
 
P100 and detergent-resistant membrane (DRM) preparation: The P100 fraction was isolated 
from cells as previously described (17). Detergent resistant membranes (DRMs) were prepared 
by solubilizing cells in lysis buffer (1% Triton X-100, 25 mM 2-(N-morpholino) ethanesulfonate 
(MES) pH 6.5, 150 mM NaCl, (MES-buffered saline or MBS) plus protease inhibitors) and 
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incubated on ice for 30 min. Relative protein concentrations were determined using Bradford 
assay and equal protein levels from each SILAC condition were mixed together. Lysates were 
adjusted to 40% sucrose by addition of an equal volume of 80% sucrose (in MBS), followed by 
successive layers of 30% and 5% sucrose. The gradients were centrifuged for 18 h at 160,000 g, 
4 ºC and the white, light-scattering band appearing between 30% and 5% sucrose collected. The 
extracted layer was diluted out approximately three-fold with MBS and pelleted by 
centrifugation at 160,000 g for 2 h, 4 ºC. All steps above were carried out at 4 ˚C. 
 
In-solution digest and SCX fractionation: Samples were resuspended or diluted with 1% 
sodium deoxycholate in 50 mM NH4HCO3 and heat solubilized for 10 min at 95 ºC. 50 µg of 
sample was reduced with 1 µg DTT, alkylated with 5 µg IAA and trypsin digested. An equal 
volume of 3% acetonitrile, 1% trifluoroacetic acid, 0.5% acetic acid was added to acidify the 
sample. In some experiments, digested peptides were also further fractionated by SCX (strong 
cation exchange chromatography) into 5 fractions using 0, 20, 50, 100 and 500 mM 
NH4CH3COO.  
 
LC-MS/MS, database searching and SILAC quantitation: Samples (4 g) were analyzed 
using a 1200 Series nano HPLC and Chip-Cube Q-TOF 6510 (Agilent Technologies). Peptides 
were resolved by 160 nl (75 mm * 150 μm) high capacity C18 reverse phase chip with 55 min 
gradient from 0 to 45 % acetonitrile with the Vcap 1850 V, fragmentor 175 V. Precursor ions 
were selected in the range of 100-3200 m/z and fragment ions at 59-3200 m/z; reference ion mix 
was applied. 
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          SILAC samples were analyzed in auto MS/MS mode, with 8 MS and 4 MS/MS per 
second. Mass spectra extraction, database searching and quantitative ratios were performed using 
Spectrum Mill software (Agilent, A03.03) against Swissprot Human database (release-2010_03 
containing 23,000 entries). Cysteine carbamidomethylation and SILAC amino acids N-Lys, 
13
C6
15
N2-Lys, N-Arg and 
13
C6
15
N4-Arg were used as a fixed/mix modifications as appropriate 
and oxidized methionine was selected as variable modification. Other parameters include up to 2 
miss cleavages for trypsin; ±20 ppm and ±50 ppm accuracy for MS and MS/MS measurements 
respectively. Positive identification required a protein score > 11, peptide score > 10, and > 60 % 
scored peak intensity (SPI). Single peptide identifications were excluded from further analysis. 
Mean SILAC ratio and standard deviation was calculated using all the peptide ratios matched to 
a protein, and p-values were calculated using the peptide SILAC ratios. False Discovery Rates 
were calculated by dividing the number of false positives  (identified by searching against a 
reverse decoy database (18)), by the total number of proteins identified. For each replicate the 
False Discovery Rate was <1.25%. 
 
Functional enrichment and network analysis: Proteins with a SILAC p-value < 0.05 were 
submitted to GeneGo for identification of Gene Ontology (GO) terms over represented in each 
list. Correction for multiple hypothesis testing was performed by controlling for the False 
Discovery Rate at p=0.05. GeneGo networks were built using the shortest path and 2 connections 
algorithm. Low trust interactions and unconnected nodes were removed. 
 
Western Blotting: Samples were resolved on SDS-PAGE gels and transferred to polyvinylidene 
difluoride using wet transfer. The membranes were blocked in 5% milk powder and then probed 
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with primary antibody for 1 h. After washing, the membrane was incubated with the appropriate 
horseradish peroxidase-coupled secondary antibody for 1 h and then developed using 
SuperSignal West Pico chemiluminescence and captured on film (Kodak). 
 
Immunofluorescence: Cells were grown on coverslips, transiently transfected and fixed in 4% 
paraformaldehyde after 24 h. For cholesterol staining, the coverslip was incubated with 50 µg/ml 
filipin for 2 h in the dark. Coverslips were washed 3 times with phosphate-buffered saline (PBS), 
mounted and visualized. For all other staining the coverslips were fixed in 4% 
paraformaldehyde, then permeabilized and blocked in 0.1% Triton-X, 1% BSA in PBS for 30 
min. Anti-caveolin-1, anti-filamin A or Texas Red conjugated phalloidin was incubated on the 
coverslips for 1 h. Where necessary, after washing in PBS, the appropriate secondary antibody 
was incubated for another hour. Coverslips were washed in PBS, mounted using Vectashield and 
visualized using a Zeiss Meta 510 confocal microscope.  
 
Cholesterol Assay: Cholesterol assay was performed using the Amplex Red cholesterol assay 
kit (Life Technologies) according to the manufacturer’s instructions. 
 
Results 
PTRF expression alters the PC-3 proteome. 
To gain a comprehensive view of cellular changes induced upon PTRF expression, we used 
SILAC with subcellular fractionation to quantitatively analyze the effect of PTRF expression on 
the PC-3 sub-proteomes. Based on the potential caveolar role of PTRF, we focused on four 
fractions: secreted proteins, secreted vesicles (prostasomes), total membrane fraction prepared as 
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a pellet after 100,000 g spin (P100), or detergent-resistant membrane (DRM), a fraction enriched 
in lipid raft microdomains (Figure 1A). Equal amount of total cell lysate from SILAC-labeled 
PC-3 cells stably expressing GFP (no PTRF expression) or GFP-PTRF (PTRF mainly localized 
to caveolae) (data not shown) were combined. The P100 or the DRM fractions were isolated and 
then analyzed by mass spectrometry (Figure 1A). The secretome was collected by growing cells 
in serum free media for 24 h and using equal protein amount of conditioned media for each cell 
type. No significant difference was observed in the viability of cells grown in serum free media 
(93.12 ± 7.62%) compared to cells grown in 10% serum containing media (100%). The vesicular 
component of the secretome (also termed prostasomes), was further fractionated from the 
secretome and then both fractions were analyzed by mass spectrometry (Figure 1A). An overall 
mean was calculated for each protein using SILAC ratios for peptides from the 4 independent 
measurements (Table S1 and S2) and then analyzed for proteins significantly changed (p value ≤ 
0.05) upon PTRF expression. 
 
We found that PTRF expression significantly decreased 136 (25%) from the 544 proteins 
identified in the P100 fraction (Figure 1B). In the DRM fraction, 103 proteins (29%) were 
decreased with PTRF expression, from a total of 358 proteins quantified (Figure 1B). Very few 
proteins were increased in abundance in the P100 or DRM fractions, 5 and 6 respectively (Figure 
1B). PTRF expression also caused a significant reduction in proteins from the secreted and 
prostasome fractions: 114 proteins (31%) were secreted less with PTRF expression from a total 
of 370 proteins identified, and 112 proteins (30%) decreased from a total of 367 proteins in the 
prostasome (Figure 1B). In contrast, very few proteins were increased in the secretome and 
prostasome, 9 and 11 respectively (Figure 1B). Importantly PTRF expression did not alter the 
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total protein content of any of the fractions (Figure 1C). These results reveal a specific change in 
the membrane targeting and/or secretion of a subset of proteins upon PTRF expression in PC-3 
cells. 
 
PTRF modulates secretion pathways to reduce the secretion of a subset of proteins. 
Previously we reported PTRF expression reduced PC-3 cell migration though collagen-coated 
Boyden chamber partly via reduction of MMP9 secretion (15). Since cell migration and invasion 
requires co-ordination between cellular events and secreted proteases, we examined the 
quantitative proteomics data for proteins with a role in cancer and cell migration. Pathways 
enrichment analysis using GeneGo software revealed that PTRF expression most significantly 
reduces the secretion of proteins involved in cell adhesion and cytoskeleton remodeling (Figure 
2A). Interestingly, PTRF modulated similar pathways in the prostasome fraction. Since the 
prostasome is a subfraction of the secretome, one possible explanation for the overlap is that 
PTRF expression specifically attenuated the secretion of vesicles. To examine this possibility, we 
analyzed the proteins common to the secretome and prostasome fraction (Figure 2B). The result 
shows that 244 proteins (66%) were identified in both fractions, indicating that prostasomes 
contribute a significant portion of total secreted proteins. In the subset of proteins significantly 
changed by PTRF expression, 61 (~50%) were common to the secretome and prostasome, 
meaning that the reduction in secreted proteins upon PTRF expression could only be partially 
explained by a reduction in prostasomal proteins.  
 
Closer inspection of the proteins reduced in both the secretome and prostasome fractions by 
PTRF expression identified a number of proteins with established links to cancer and in 
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particular metastasis, including extracellular matrix proteins, secreted proteases, and cytokines 
(Table 1). We selected two proteins that have been previously implicated in prostate cancer (19-
21) for verification by western blotting, namely kallikrein 6 (KLK6) and interleukin-6 (IL-6). To 
cross-validate the stable cell line quantitative proteomics results, we chose transient transfection 
of wild type PC-3 cells for these experiments. Conditioned media collected from PC-3 cells 
transiently transfected with control GFP or GFP-PTRF plasmids were immunoblotted with 
antibodies against KLK-6 and IL-6. This result confirmed that expression of PTRF reduced 
secreted KLK-6 and IL-6 (Figure 2C, left panel). Whole cell lysates of GFP and GFP-PTRF cells 
showed no change in expression levels (Figure 2C, right panel) indicating that PTRF expression 
does not affect total cellular levels of KLK-6 and IL-6 but rather specifically modulates their 
secretion.  
 
PTRF expression alters the DRM-associated pool of actin cytoskeletal proteins. 
Quantitative changes in the P100 and DRM fractions were further analyzed to determine 
potential cellular mechanisms linking PTRF expression to the observed reduction in secreted 
proteins. Proteins that were significantly changed (p-value ≤ 0.05) by PTRF in the P100 and 
DRM fractions were analyzed using GeneGo software. This analysis identified regulation of 
cytoskeleton rearrangement as the most significant pathway (Figure 3A), with a p-value of 
2.09x10
-11
 for the DRM and 1.51x10
-7
 for the P100 fraction. In agreement with previous reports 
(22, 23), our DRM fraction was highly enriched in cytoskeletal proteins and furthermore, many 
were reduced by PTRF expression (Table 2). This includes structural and regulatory proteins 
such as actin, 14-3-3, epiplakin, filamin A, myosin 9 and 11, plastin, spectrin, and stomatin like 
protein 2. In addition, many of the structural cytoskeletal proteins such as actin, myosins and 
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spectrins were changed in the DRM fraction and not in the P100 fraction. This result raises the 
possibility that PTRF expression altered the cytoskeleton link to lipid raft membrane 
microdomains. Consistent with this, one of the proteins identified in our proteomic study to be 
reduced in the DRM by PTRF expression was filamin A, a filamentous actin binding protein that 
is thought to link caveolae to the actin cytoskeleton (24).  
 
To verify the quantitative proteomics data, we first utilized fluorescence microscopy to examine 
the morphology of the actin cytoskeleton by staining with phalloidin which stains filamentous 
actin. No obvious difference was observed in the distribution between GFP and GFP-PTRF 
expressing cells (Figure 3B). Similarly, immunofluorescence microscopy using an antibody to 
filamin A showed no obvious difference under these conditions (Figure 3C). In agreement, 
western blots of whole cell lysate isolated from transient GFP or GFP-PTRF expressing cells 
showed no difference in total protein levels of β-actin or filamin A (Figure 3D, left panel). In 
stark contrast, western blots of the DRM fractions demonstrated a substantial reduction in β-actin 
and filamin A protein levels in GFP-PTRF expressing cells, but no change in flotillin, a marker 
of lipid rafts (Figure 3D, right panel). These results confirmed our proteomic findings and 
suggest that PTRF expression attenuated the recruitment of cytoskeletal proteins β-actin and 
filamin A to DRMs in PC-3 cells.  
 
Recent literature supports a role for the actin cytoskeleton in the early stages of secretion 
pathways. Secretory pathways rely on Golgi derived carrier vesicles to deliver their cargo to the 
required destination. Furthermore, during the sorting process, cargo proteins are segregated into 
distinct membrane microdomains. To gain insight into secretory pathways affected by PTRF 
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expression, proteins identified by proteomics to be significantly changed in the P100 and DRM 
fractions were categorized according to function and those with a reported role in membrane 
trafficking were further analyzed for pathways associated with secretion (Table 3). This analysis 
revealed an enrichment of proteins associated with trafficking from the endoplasmic reticulum 
(ER), Golgi and lysosome. In particular, aminopeptidase N, protein LYRIC, SEC24C, reticulon-
4, TMED 10, TMED 2, TMED 4, vesicle-fusing ATPase, and SEC22b have been associated with 
the ER-Golgi intermediate compartment (ERGIC) or trafficking between the ER and Golgi, and 
were all reduced in the P100 fraction upon PTRF expression. Fewer trafficking proteins were 
regulated by PTRF expression in the DRM fraction, with aminopeptidase N, kinectin and 
reticulon-4 the only ER associated proteins reduced in this fraction. Together our data suggests 
that PTRF alters the lipid raft associated actin cytoskeleton which may in turn affect trafficking 
between the ER and the Golgi.  
 
PTRF expression modifies cholesterol dynamics in DRMs. 
One factor that regulates the association between lipid rafts and the actin cytoskeleton is 
cholesterol (25-27). Caveolin-1 binds cholesterol and is a major mediator of cholesterol transport 
to the plasma membrane (28, 29). Therefore we investigated whether PTRF expression modifies 
the cholesterol dynamics in lipid rafts, possibly accounting for the changes in the actin 
cytoskeleton. Our proteomics study identified a small subset of proteins from the DRM fraction 
that play a role in cholesterol transport (Table 4) and none in the P100 fraction. GeneGo was 
used to uncover potential interactions between the subset of cholesterol trafficking proteins and 
the subset of cytoskeletal proteins identified in the DRM fraction (Table 2 and 4). The network 
diagram illustrated a direct relationship between key cytoskeletal proteins such as -actin 
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(ACTB) and filamin A with cholesterol regulating proteins caveolin-1 and Annexin IV (Figure 
4). In addition, many of the cytoskeletal proteins regulate transcription factors SMAD3, 
FOXO3A, c-Abl, NCX1 and c-Myc that in turn regulate the expression of cholesterol regulating 
proteins.  
 
We went on to measure cholesterol levels in whole cell lysate, P100, and the DRM fraction of 
PC-3 cells transiently expressing GFP or GFP-PTRF. PTRF expression did not affect cholesterol 
levels in the whole cell lysate or the P100 fraction, but induced a decrease in cholesterol levels in 
the DRM fraction (Figure 5A). Curiously, this was not accompanied by a significant change in 
the protein content of the DRM fractions (Figure 1C). To examine the subcellular location of 
cholesterol-enriched membranes, PC-3 GFP and PC-3 GFP-PTRF cells were stained with filipin, 
a UV-light fluorescent stain that binds sterols. Control cells transfected with GFP exhibited 
distinct plasma membrane staining as well as an intracellular vesicular pool of cholesterol 
(Figure 5B). PTRF expressing cells also displayed strong plasma membrane staining but in 
contrast to control cells, the intracellular vesicular pool was more pronounced (Figure 5B). 
Taken together, these data indicate that PTRF expression alters cholesterol distribution.  
 
To corroborate decreased cholesterol levels in the DRM with changes in the actin cytoskeleton, 
we explored the effects of additional cholesterol or depleting cholesterol from the plasma 
membrane using methyl-β-cyclodextrin (MβCD). We examined the distribution of cholesterol, 
caveolin-1 and filamentous actin by using filipin, anti-caveolin-1 antibody and phalloidin, 
respectively.  PC-3 cells treated with 8µM cholesterol showed substantially elevated intracellular 
cholesterol levels, and concurrently a greater pool of intracellular caveolin-1 was observed 
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compared to control cells (Figure 6). Strikingly phalloidin staining illustrated less distinct 
cortical actin and more dispersed filamentous actin in cholesterol treated cells compared to 
control cells (Figure 6). Treatment with MβCD resulted in a clear decrease in filipin staining, and 
plasma membrane caveolin-1 but a greater intracellular pool for both (Figure 6). The 
corresponding phalloidin stain displayed enhanced cortical actin staining (Figure 6). These 
results demonstrate that manipulation of cholesterol levels in PC-3 cells does in fact impact on 
regulation of the actin cytoskeleton.  
 
Disruption to cholesterol alters secretion.        
Recent literature highlights the important role cholesterol levels and the actin cytoskeleton play 
in multiple secretion pathways (30-32). Therefore we speculated that the observed changes in 
subcellular cholesterol and actin cytoskeletal distribution induced by PTRF expression would 
also account for the perturbed secretion. To test this hypothesis, we next incubated PC-3 cells 
with vehicle, 8µM cholesterol or 500µM MβCD for 24h in serum free media, collected the 
secreted fraction, and immunoblotted for actin, caveolin-1 and KLK-6. The addition of 
cholesterol reduced the secreted levels of all three proteins (Figure 7). In striking contrast, 
MβCD had differential effects depending on the protein. Secreted levels of actin were clearly 
increased with MβCD treatment (Figure 7). Secreted caveolin-1 was slightly reduced with 
MβCD but not nearly as much as seen with cholesterol addition. Finally, KLK-6 levels were 
substantially decreased in the secretome with MβCD (Figure 7). The conflicting results likely 
reflect the different secretory pathways of each protein. It is probable that adding cholesterol 
affects multiple secretory pathways whereas MβCD may target a more specific subset.   
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Discussion 
In this study we found that expression of PTRF in the caveolin-1 positive cell line PC-3 reduced 
the secretion of a specific subset of proteins including extracellular matrix proteins, secreted 
proteases, cytokines and growth factors. Many of these secreted proteins are known to be 
involved in prostate cancer progression. As an example, elevated levels of IL-6 have been 
reported in the sera of prostate cancer patients (19, 20). Despite evidence linking IL-6 levels to 
the progression of prostate cancer, preliminary studies using IL-6 monoclonal antibodies to 
specifically target IL-6 in advanced prostate cancer have given poor outcomes in the clinic (33). 
Therefore, targeting a single molecule may not represent the ideal solution to attack prostate 
cancer. Here we show that by expressing PTRF in PC-3 cells, secretion of multiple factors 
associated with prostate cancer progression is reduced. These results reveal an exciting, novel 
therapeutic option that could potentially target a broad spectrum of cancer promoting factors 
secreted by tumor cells, namely, modulation of lipid raft composition and function by expression 
of PTRF. Thus, PTRF therapy has the potential to target the tumor microenvironment as well as 
the cancer cells since many of the secreted factors reduced by PTRF expression have pleiotropic 
activities on the surrounding stromal cells as well as the cancer cells.  
 
PTRF specifically reduced the secretion of IL-6 and KLK6 with no affect on total cellular levels 
indicating that PTRF influences secretory pathways. This is most likely explained by the PTRF 
induced sequestration of non-caveolar caveolin-1 to form caveolae. However, we cannot exclude 
the possibility that PTRF may also function outside of caveolae. Further evidence of caveolin-1 
mediated effects on secretion comes from studies showing that modulation of caveolin-1 
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expression levels affects IL-6 secretion. Ectopic expression of caveolin-1 in mouse lung alveolar 
type-1 (AT-1) cells increased LPS-modulated IL-6 production (34). However, in contrast 
caveolin-1 expression in the macrophage cell line RAW264.7 decreased LPS modulated IL-6 
secretion levels (35). These inconsistencies may reflect differential caveolin-1 and PTRF 
expression in the two cell types.  
 
To unveil specific secretory pathways altered by PTRF, our analysis of the P100 and DRM 
fractions demonstrated that PTRF induced a change in the expression and/or membrane 
recruitment of proteins that are associated with secretion at several cell compartments, namely 
the ER, Golgi and lysosomes. However, we observed particular enrichment of proteins that 
function in ER to Golgi transport. Furthermore, PTRF regulated the recruitment of cytoskeletal 
proteins actin and spectrin to DRMs. Actin is important for Golgi-derived carrier vesicle 
biogenesis as well as transport from the Golgi to the ER. Spectrin βII functions in ER to Golgi 
transport and Golgi architecture (36). Therefore it is likely that PTRF expression impacts the 
actin cytoskeleton associated with the ER and Golgi. An important role for actin dynamics at the 
Golgi and in early stages of secretory pathways derived from the Golgi is well documented, 
reviewed in (37), however, actin based mechanisms between the ER and Golgi are less well 
defined. Different classes of Golgi derived vesicles bind to distinct sets of actin binding proteins 
(38). Given that PTRF modifies the abundance of a third of proteins recruited to membranes, we 
speculate that this would disrupt a number of vesicles types, and thereby explain why we 
observed a reduction in protein secreted by more than one pathway.  
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The actin cytoskeleton is linked with many aspects of membrane trafficking and its function is 
particularly well documented at the plasma membrane (39). Intriguingly, our results suggest that 
PTRF induced changes to the actin cytoskeleton are concentrated at ER and Golgi trafficking, in 
turn affecting secretion pathways. A number of factors may contribute to this trend: Firstly, the 
Golgi is central to many membrane trafficking pathways, being the meeting point for endocytic 
and exocytic vesicles. Moreover, Golgi derived vesicles are directed to many cellular 
compartments including endosomes, ER and plasma membrane. Therefore disruption of 
membrane trafficking may have the greatest influence on the Golgi. Secondly, these effects are 
likely to be compounded by the multiple roles for actin at the Golgi including maintenance of 
architecture, homeostasis, signaling and transport (36). Finally, PTRF induced changes to lipid 
rafts and membrane trafficking might upset the delicate balance of membrane internalized at the 
plasma membrane and synthesized at the ER. The Golgi would be extremely sensitive to these 
changes due to the large amount of cargo continuously passing through. 
 
An association between the actin cytoskeleton and lipid rafts is well documented (40, 41). 
Caveolae lipid rafts are thought to tether to the cortical actin cytoskeleton through binding of 
filamin A and filamin B (24). Studies indicate that in a phosphorylation dependent manner, 
filamin A regulates a number of caveolin-1 functions: the distribution of caveolin-1 along actin 
stress fibers, anchoring of caveolin-1 vesicles at the plasma membrane, and internalization of 
caveolae (42, 43). We have shown that PTRF expression reduced the abundance of filamin A 
and filamin B in the DRM fraction, possibly via caveolae formation. Therefore, it is possible that 
non caveolar caveolin-1 domains attach to the cytoskeleton differently from caveolae. 
Furthermore, stable over expression of caveolin-1 in a breast cancer cell line increased 
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expression levels of filamin A (43). Our data suggests that in addition to caveolin-1 levels, 
caveolin-1 microdomain structure also modulates the abundance of filamin A and B in lipid rafts.   
 
One of the major constituents of lipid rafts is cholesterol. Cholesterol levels are elevated in PC-3 
cells compared with normal prostate epithelial cell lines and the caveolin-1 deficient cell LNCaP 
(44). Caveolin-1 binds directly to cholesterol and regulates its trafficking (25-29). Expression of 
PTRF significantly impacts lipid raft structure in PC-3 cells by inducing the formation of 
caveolae (5). We found that PTRF expression specifically reduced cholesterol in lipid rafts and 
appeared to redistribute it partly to intracellular vesicles. Moreover, by modulating cellular 
cholesterol levels we demonstrated altered secretion of actin, IL-6 and KLK6 indicating that 
cholesterol dynamics in turn regulate secretion pathways. Consistent with our observations for a 
role of cholesterol in secretion, others have shown that cholesterol depletion blocked the 
formation of regulatory and secretory vesicles from AtT-20 cells (31), reduced zymogen 
granules and increased amylase secretion in pituitary cells (45), and the release of prostasomes 
from PC-3 cells (14). Although our study and others clearly link changes in cholesterol and 
cytoskeletal dynamics to alterations in a range of secretory pathways, the mechanisms remain to 
be elucidated. Further insight has come from a study that shows that PIP2 induced actin 
polymerization around lipid raft enriched membrane vesicles, forming comet tails which directed 
them to the cytoplasm (46). In addition, the authors show that depletion of membrane cholesterol 
using MβCD reduced actin comets, indicating an essential role for cholesterol and lipid rafts in 
vesicular trafficking. The correct balance of cholesterol on vesicles is critical since cholesterol 
accumulation on late endocytic compartments impairs their mobility by interfering with Rab7 
activity (47). Together these studies and ours indicate that non-caveolar caveolin-1 in PC-3 cells 
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have elevated lipid raft cholesterol, which impacts on regulation of actin cytoskeleton and 
secretory pathways.  
 
Taken together, our data are consistent with a model in which the cholesterol-rich non-caveolar 
caveolin-1 microdomain recruits elevated levels of cyoskeletal proteins, in particular filamin A 
and B which are likely to be vital in tethering caveolin-1 to actin filaments. PTRF induced 
sequestration of non-caveolar caveolin-1 to form caveolae, altering cholesterol dynamics and 
lipid raft composition in PC-3 cells. As a result, cytoskeletal proteins recruited to lipid rafts are 
modified, impacting multiple secretory pathways. Therefore, the unique non caveolae caveolin-1 
microdomains of PC-3 cells, created by expression of caveolin-1 but not PTRF, has allowed 
these cells to develop a mechanism to increase secretion of proteases, cytokines and growth 
factors, potentially increasing their metastatic ability. Most importantly, we show these effects 
were neutralized by PTRF expression. Cell motility is intimately associated with cytoskeletal 
remodeling and membrane trafficking, since in order for cells to migrate, actin polymerization is 
required for membrane extensions and membrane turnover. In agreement with our model, PTRF 
expression was shown to reduce cell migration in PC-3 cells (15). Our study brings to light the 
different cellular mechanisms resulting from non caveolae and caveolae caveolin-1 and the 
potential for developing novel therapies designed to target caveolin-1 and its microdomain 
structure on the plasma membrane as a means to improve patient outcome. Although we 
investigated prostate cancer cells in this study, this type of strategy has the potential to be applied 
to other tumor types involving caveolin-1.      
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Figure Legends 
Figure 1: PTRF expression induced changes in the PC-3 proteome. (A) SILAC labeling was 
performed by incorporating Lys’0’, Arg’0’ into PC-3 GFP cells and Lys’8’,Arg’10’ into PC-3 
GFP-PTRF cells. Cells were fractionated into secretome, prostasome, P100, and DRM 
compartments, trypsin digested, desalted using SCX/C18, and analyzed by LC MS/MS. (B) Pie 
charts show the number of proteins with significantly different (p ≤ 0.05) abundance in the P100, 
DRM, secretome and prostasome fractions upon PTRF expression, and proteins not changed. (C) 
Protein content was determined using BCA assay for whole cell lysates (WCL), P100, DRM, and 
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secretome fraction of PC-3 GFP and GFP-PTRF cells. The graph shows the mean protein 
concentrations ± SEM (n=3). 
 
Figure 2: PTRF expression affects multiple secretory pathways to reduce a subset of 
secreted proteins that function in cell adhesion and cytoskeleton remodeling. (A) Bar chart 
of GeneGo analysis displaying the most highly enriched molecular pathways for the secretome 
and prostasome fraction. (B) Venn diagrams displaying proteins common to the secretome and 
prostasome fraction (top) and those common in the list of proteins significantly changed (p ≤ 
0.05) upon PTRF expression (bottom). (C) PC-3 cells were transiently transfected with GFP or 
GFP-PTRF. The secretome was collected from serum free media incubated on the cells for 24 h. 
Whole cells lysates were isolated in parallel. Western blotting was performed to analyze changes 
in protein expression by probing with antibodies against PTRF, caveolin-1, KLK-6 and IL-6. 
Equal loading was shown by coomassie stain. Whole cells lysates showed no difference in 
protein levels between GFP and GFP-PTRF cells however, secreted levels of KLK-6 and IL-6 
were reduced in GFP-PTRF cells. 
 
Figure 3: PTRF expression alters the DRM-associated pool of actin cytoskeletal proteins. 
(A) Bar chart of GeneGo analysis displaying the most highly enriched biological processes for 
the P100 and DRM fraction. Cells were stained with phalloidin (B) or antibody against filamin A 
(C). Localization was analyzed by fluorescent confocal microscopy. No obvious change in 
distribution was observed between GFP and GFP-PTRF expressing cells. Scale bar = 20μM (D) 
Whole cell lysates or DRMs were isolated and analyzed by western blotting. Blots were probed 
with antibody against PTRF to show transfection, caveolin-1, β-actin, filamin A, and flotillin. 
27 
 
The whole cells lysates showed no difference in protein levels between GFP and GFP-PTRF 
cells however, the DRM fraction showed a reduction in β-actin and filamin A in GFP-PTRF 
cells. 
 
Figure 4: Network analysis to uncover relationships between actin cytoskeletal proteins 
and cholesterol regulating proteins. The network diagram illustrates a direct relationship 
between key cytoskeletal proteins such as actin (ACTB) and filamin A with cholesterol 
regulating proteins caveolin-1 and annexin IV (Figure 7). In addition, many of the cytoskeletal 
proteins regulate transcription factors SMAD3, FOXO3A, c-abl, NCX1 and c-myc that in turn 
regulate the expression of cholesterol regulating proteins. Legend: Green circles – objects used to 
build pathway from. Red circles – objects used to build pathway to. Green arrows – positive 
effect. Red arrow – negative effect. Blue symbol – generic binding protein. Blue receptor symbol 
– generic receptor. Orange reverse arrow symbol – protein kinase. Yellow symbol – generic 
enzyme. Red symbol – transcription factor. Purple symbol – generic channel. 
 
Figure 5: PTRF expression changes cholesterol dynamics in lipid rafts. PC-3 cells were 
transiently transfected with GFP or GFP-PTRF. (A) Whole cell lysates, P100, or DRM fractions 
were isolated from the cells and a cholesterol assay performed. The graph shows the mean 
cholesterol level ± SEM (n=3). (B) GFP and GFP-PTRF cells were stained with filipin and 
analyzed by fluorescent confocal microscopy to detect cholesterol localization. GFP-PTRF 
expressing cells displayed a more pronounced intracellular pool of cholesterol. Scale bar = 
20μM. 
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Figure 6: Changes in cholesterol affects the actin cytoskeleton and caveolin-1 localization. 
PC-3 cells were treated with vehicle (control), 8 µM cholesterol, or 500 µM MβCD for 24 h. 
Cells were analyzed for the localization of cholesterol with filipin, caveolin-1, and filamentous 
actin with phalloidin using fluorescent confocal microscopy. Scale bar = 20μM. 
 
Figure 7: Cholesterol dynamics modulates secretion. (A) The secretome was isolated from 
PC-3 cells incubated with serum free media for 24 h. During the final 6 h of incubation, cells 
were supplemented with vehicle (control), 8 µM cholesterol, or 500 µM MβCD. Changes in 
secretion were analyzed by western blot analysis. Antibodies against β-actin, caveolin-1 and 
KLK-6 were used to detect secreted protein levels. Equal loading was shown by coomassie stain.  
 
Table 1 
List of selected proteins that were reduced in the secretome and prostasome fraction of SILAC 
PC-3 cells expressing PTRF. Protein levels were quantified by mean SILAC (heavy/light) ratio 
with PTRF expression over four independent experiments. No. Ob = Number of SILAC ratios 
used for quantification.  No. Pep = Number of unique peptides observed. Proteins were classified 
by function. 
 
  
Secretome Prostasome 
Accession Protein name 
No. 
Ob 
No. 
Pep ratio ± SD p-value 
No. 
Ob 
No. 
Pep ratio ± SD p-value 
  
Extracellular Matrix Protein   
 
           
P12109 
Collagen alpha-1(VI) 
chain  103 16 0.42 ± 0.12 < 0.001 62 13 0.42 ± 0.09 0.015 
  
Secreted Proteases               
Q9Y337 Kallikrein-5  3 2 0.28 ± 0.02 0.007 2 1 0.27 ± 0.01 0.010 
Q92876 Kallikrein-6  27 2 0.54 ± 0.07 0.012 19 2 0.55 ± 0.08 0.020 
29 
 
P00749 
Urokinase-type 
plasminogen activator  179 12 0.40 ± 0.08 < 0.001 139 11 0.45 ± 0.02 0.030 
P80188 
Neutrophil gelatinase-
associated lipocalin  161 10 0.42 ± 0.12 < 0.001 209 11 0.42 ± 0.08 0.050 
  
Cytokines/Growth Factors               
P05231 Interleukin-6  41 7 0.10 ±0.06 < 0.001 28 6 0.10 ± 0.07 0.006 
P08476 Inhibin beta A chain  111 13 0.29 ± 0.12 < 0.001 30 11 0.24 ± 0.13 0.006 
P61812 
Transforming growth 
factor beta-2  62 7 0.60 ±0.11 0.006 55 4 0.59 ± 0.07 0.020 
O00622 Protein CYR61  30 6 0.40 ± 0.21 0.004 14 4 0.31 ± 0.11 0.006 
 
Table 2 
List of cytoskeletal proteins reduced in abundance in the DRM and the corresponding ratio from 
the P100 fraction upon PTRF expression. Protein levels were quantified by mean SILAC 
(heavy/light) ratio with PTRF expression over four independent experiments. No. Ob = Number 
of SILAC ratios used for quantification. No. Pep = Number of unique peptides observed. 
 
  
DRM P100 
Accession Protein name 
No. 
Ob 
No. 
Pep Ratio ± SD 
P-
value 
No. 
Ob 
No. 
Pep Ratio ± SD 
P-
value 
P63104 14-3-3 protein zeta/delta 25 5 0.49 ± 0.22 0.028 43 6 0.55 ± 0.15 0.010 
P62736 Actin 116 19 0.46  ± 0.17 0.039 100 18 0.81 ± 0.46 0.941 
P60709 Actin, cytoplasmic 1 120 19 0.48  ± 0.17 0.045 98 18 0.67 ± 0.15 0.591 
P50995 Annexin A11  85 13 0.55  ± 0.15 0.040    Not found    
P80723 
Brain acid soluble 
protein 1  48 9 0.54  ± 0.14 0.040 35 8 0.30 ± 0.11 0.003 
P12830 Cadherin-1  4 3 0.07  ± 0.03 0.002     Not found   
P58107 Epiplakin  55 151 0.51  ± 0.25 0.029 20 76 0.52 ± 0.11 0.020 
P21333 Filamin-A  15 5 0.46  ± 0.23 0.030 14 4 0.46 ±  0.14 0.008 
O75369 Filamin-B  14 5 0.35  ± 0.18 0.011     Not found   
P05556 Integrin beta-1  3 2 0.27  ± 0.08 0.019 82 10 0.41 ± 0.12 0.007 
Q9UHB6 
LIM domain and actin-
binding protein 1  6 4 0.42  ± 0.27 0.054    Not found    
P35749 Myosin-11  2 4 0.15  ± 0.09 0.007     Not found   
P35579 Myosin-9  6 4 0.33  ± 0.02 0.013 3 3 0.55 ± 0.32 0.247 
P13796 Plastin-2  2 1 0.13  ± 0.00 0.005 2 1 0.32 ± 0.03 0.023 
P61225 Rap-2b  21 3 0.51  ± 0.14 0.048 3 2 0.69 ± 0.23 0.647 
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Q13813 Spectrin alpha chain 79 14 0.49  ± 0.22 0.032 7 2 0.65 ± 0.09 0.528 
Q01082 
Spectrin beta chain, brain 
1  11 5 0.40  ± 0.21 0.015    Not found    
O15020 
Spectrin beta chain, brain 
2  2 1 0.18  ± 0.01 0.012    Not found    
Q9UJZ1 Stomatin-like protein 2  79 9 0.52  ± 0.28 0.032 15 2 0.40 ± 0.22 0.007 
 
Table 3 
List of proteins associated with trafficking that were significantly changed in the P100 and DRM 
fractions of SILAC PC-3 cells expressing PTRF. Protein levels were quantified by mean SILAC 
(heavy/light) ratio with PTRF expression over four independent experiments. No. Ob = Number 
of SILAC ratios used for quantification. No. Pep = Number of unique peptides observed. 
 
 
 
 
Accession 
Number Protein Name  Function 
No. 
Ob 
No. 
Pep Ratio 
St 
Dev 
P-
value 
P100 fraction 
 
 
   
P08195 
4F2 cell-surface antigen 
heavy chain  
targeting of LAT1 LAT2 to PM 
(CD98) 39 6 0.42 0.12 0.003 
Q96BM9 
ADP-ribosylation factor-
like protein 8A  Lysosome motility, LE 9 3 0.35 0.12 0.005 
P15144 Aminopeptidase N  ERGIC (CD13) 36 8 0.29 0.11 0.003 
P80723 
Brain acid soluble protein 
1  Cytoskeleton-PM link (NAP22) 35 8 0.30 0.11 0.003 
P08962 CD63 antigen  Lysosome, LE (LAMP3) 4 2 0.41 0.10 0.022 
Q14108 
Lysosome membrane 
protein 2  Lysosome (CD36) 3 1 0.26 0.03 0.004 
P13473 
Lysosome-associated 
membrane glycoprotein 2  Lysosome (CD107b), Adhesion 19 3 0.51 0.16 0.015 
P29966 
Myristoylated alanine-
rich C-kinase substrate  Actin-PM link 10 4 0.15 0.07 0.001 
P13796 Plastin-2  
Actin-PM link, membrane 
ruffles (LCP-1) 2 1 0.32 0.03 0.023 
Q15149 Plectin-1  
Intermediate filament and 
microtubule link, dynamics 
regulation, hemidesmosomes 264 76 0.52 0.32 0.000 
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Q86UE4 Protein LYRIC  ER, tight junction 19 6 0.47 0.15 0.009 
P53992 
Protein transport protein 
Sec24C  ER, COPII coat 29 3 0.56 0.08 0.028 
P59190 
Ras-related protein Rab-
15  
synaptic membrane, interacts 
with Rab3A 3 5 0.22 0.28 0.003 
Q9NQC3 Reticulon-4  
ER tubules, PM, regulates 
migration via ICAM and 
fibulin-5 (Nogo) 16 3 0.53 0.19 0.030 
P49755 
Transmembrane emp24 
domain-containing 
protein 10  ERGIC (TMED10) 23 3 0.54 0.13 0.023 
Q15363 
Transmembrane emp24 
domain-containing 
protein 2  
ERGIC, COPI vesicles, interacts 
with ARFGAP, (complex with 
SURF4, TMED2, TMED10) 18 3 0.54 0.15 0.040 
Q7Z7H5 
Transmembrane emp24 
domain-containing 
protein 4  ER (TMED4) 4 2 0.17 0.09 0.002 
P46459 Vesicle-fusing ATPase  
ER-Golgi and intra-Golgi 
vesicle fusion (NSF) 2 1 0.25 0.21 0.009 
O75396 
Vesicle-trafficking 
protein SEC22b  ER-Golgi SNARE 2 1 3.06 2.56 0.026 
Q10567 
AP-1 complex subunit 
beta-1  Golgi vesicle budding 26 2 0.42 0.08 0.006 
DRM fraction 
  
 
   
P08195 
4F2 cell-surface antigen 
heavy chain  
targeting of LAT1 LAT2 to PM 
(CD98) 5 2 0.18 0.10 0.004 
P15144 Aminopeptidase N  ERGIC (CD13) 140 18 0.48 0.14 0.043 
Q03135 Caveolin-1  Caveolae formation 23 2 1.99 0.41 0.038 
Q86UP2 Kinectin  
ER vesicle, kinesin-driven 
vesicle transport, accumulates at 
integrin adhesions 20 5 0.45 0.24 0.020 
Q9NX40 
OCIA domain-containing 
protein 1  Endosome 8 1 0.38 0.27 0.017 
Q56VL3 
OCIA domain-containing 
protein 2  Endosome 6 2 0.41 0.13 0.046 
P13796 Plastin-2  
Actin-PM link, membrane 
ruffles (LCP-1) 2 1 0.13 0.00 0.005 
Q969L2 Protein MAL2  Endosome-Apical PM transport 7 1 0.34 0.17 0.011 
Q9NQC3 Reticulon-4  
ER tubules, PM, regulates 
migration via ICAM and 
fibulin-5 (Nogo) 13 3 0.41 0.17 0.015 
 
Table 4 
Proteins associated with cholesterol transport in the DRM fraction that was significantly changed 
upon PTRF expression. Protein levels were quantified by mean SILAC (heavy/light) ratio with 
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PTRF expression over four independent experiments. No. Ob = Number of SILAC ratios used 
for quantification. No. Pep = Number of unique peptides observed. 
 
Accession 
number Protein name 
No. 
Ob 
No. 
Pep Ratio St Dev P-value 
Q92485 
Acid sphingomyelinase-like phosphodiesterase 
3b  5 4 0.68 0.61 0.644 
O14734 Acyl-coenzyme A thioesterase 8  3 1 0.21 0.08 0.008 
P09525 Annexin A4  33 7 0.49 0.15 0.025 
P02647 Apolipoprotein A-I  2 1 0.23 0.06 0.027 
Q03135 Caveolin-1  23 2 1.99 0.41 0.038 
O75131 Copine-3  42 6 0.53 0.15 0.040 
P30041 Peroxiredoxin-6  2 2 0.10 0.07 0.003 
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